Company profileNutraceutical & supplements#126 of 1,318 in Pakistan✓ No DRAP alerts

HYAN PHARMA

Nutraceutical & supplement manufacturer · 135 registered products

Ranked #17 of 40 companies in Blood Conditions

135 registered products 27 distinct molecules 0 DRAP alerts

135 of this company's registrations sit in the DRAP category “Nutritional Supplement / Multivitamin”, which is registered as a category rather than by molecule — so a low molecule count reflects how supplements are registered, not a small portfolio. Nutraceutical manufacturers advertise direct to consumers and are among the largest marketing spenders in the Pakistani market.

Company overview

135

registered products

distinct molecules

therapeutic classes

DRAP alerts

HYAN PHARMA is a nutraceutical and dietary-supplement manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 135 product registrations. It is the 126th largest registrant in Pakistan by product count, and ranks 17th of 40 in Blood Conditions. Its portfolio is concentrated in Blood Conditions and Cardiac Care. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by HYAN

5 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Blood Conditions 1

FerrotronRs 750

Cardiac Care 1

NormorolextraqRs 1,194.9

Other 3

PC-CureRs 166.56 Visfer-F PlusRs 5,700 Visfer-M PlusRs 142.5

Top molecules by brand count

Nutritional Supplement / Multivitamin126 brands

Testa Triticum Tricum2 brands

Enterococcus Faecium M741 brand

Potassium Chloride1 brand

Retinol1 brand

Pyridoxine1 brand

Cyanocobalamin1 brand

Manganese1 brand

Zinc1 brand

Tocopherol1 brand

Therapeutic classes

Conditions treated

Price band (DRAP official ceilings)

Registered products priced by source

DVAGO3 products · Rs 142.5 – Rs 5,700

Servaid2 products · Rs 750 – Rs 1,194.9

Median across source: Rs 972.45

Regulatory record

✓

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Wilshire Laboratories (Private) Limited13 shared molecules

MASS PHARMA (PRIVATE) LIMITED12 shared molecules

ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD.12 shared molecules

Paramount Pharmaceuticals (Pvt) Ltd.12 shared molecules

HELIX PHARMA (PRIVATE) LIMITED12 shared molecules

HIMONT PHARMACEUTICALS (PVT) LTD.11 shared molecules

MARTIN DOW PHARMACEUTICALS (PAK) LTD.11 shared molecules

ABBOTT LABORATORIES (PAKISTAN) LIMITED.11 shared molecules

KRKA-PAK PHARMACEUTICAL & CHEMICAL WORKS11 shared molecules

GlaxoSmithKline Pakistan Limited11 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Wilshire Laboratories (Private) Limited holds 132 molecules not in this portfolio

MASS PHARMA (PRIVATE) LIMITED holds 129 molecules not in this portfolio

ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD. holds 156 molecules not in this portfolio

Get the full profile for HYAN

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included